相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms
Jan Stetka et al.
BLOOD (2023)
NF-κB in monocytes and macrophages - an inflammatory master regulator in multitalented immune cells
Marion Mussbacher et al.
FRONTIERS IN IMMUNOLOGY (2023)
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Obesity-induced inflammation exacerbates clonal hematopoiesis
Santhosh Kumar Pasupuleti et al.
JOURNAL OF CLINICAL INVESTIGATION (2023)
Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
Ayalew Tefferi et al.
CANCER RESEARCH (2022)
Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody
Denis Tvorogov et al.
EMBO REPORTS (2022)
An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms
Graciela Rabadan Moraes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis
Lilian Varricchio et al.
FRONTIERS IN ONCOLOGY (2022)
Contemporary and future strategies in polycythemia vera
Julian A. Waksal et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2022)
Molecular Pathogenesis of Myeloproliferative Neoplasms
Benjamin Rolles et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2022)
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
Mathieu Gigoux et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
Shivam Rai et al.
NATURE COMMUNICATIONS (2022)
Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms
Selena Zhou et al.
ACTA HAEMATOLOGICA (2021)
Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease
Christopher S. Marnell et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2021)
Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling
Daniel Hormaechea-Agulla et al.
CELL STEM CELL (2021)
Mutations and thrombosis in essential thrombocythemia
Paola Guglielmelli et al.
BLOOD CANCER JOURNAL (2021)
Molecular pathogenesis of the myeloproliferative neoplasms
Graeme Greenfield et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
INSL4 as prognostic marker for proliferation and invasiveness in Non-Small-Cell Lung Cancer
Damiano Scopetti et al.
JOURNAL OF CANCER (2021)
Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease
Christina K. Ferrone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Leukemia secondary to myeloproliferative neoplasms
Andrew J. Dunbar et al.
BLOOD (2020)
Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms
Rasmus K. Pedersen et al.
CANCER MEDICINE (2020)
Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1
Adrien Bosseboeuf et al.
CANCERS (2020)
Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN
Gajalakshmi Ramanathan et al.
CANCERS (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Adipocyte Fatty Acid Transfer Supports Megakaryocyte Maturation
Colin Valet et al.
CELL REPORTS (2020)
Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells
Erik L. Bao et al.
NATURE (2020)
Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
Sophie Allain-Maillet et al.
CANCERS (2020)
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
Julian Grabek et al.
CELLS (2020)
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms
Fiorella Schischlik et al.
BLOOD (2019)
Modulation of megakaryopoiesis and platelet production during inflammation
Genevieve Couldwell et al.
THROMBOSIS RESEARCH (2019)
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Florian Perner et al.
CELLS (2019)
IL-1β Secreted from Mutant Cells Carrying JAK2-V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression
Shivam Rai et al.
BLOOD (2019)
The role of ASXL1 in hematopoiesis and myeloid malignancies
Shuhei Asada et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
Targeted therapies for myeloproliferative neoplasms
Bing Li et al.
BIOMARKER RESEARCH (2019)
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto et al.
HAEMATOLOGICA (2018)
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy
M. O. Holmstrom et al.
LEUKEMIA (2018)
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto et al.
HAEMATOLOGICA (2018)
Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells
Monique F. Smeets et al.
BLOOD (2018)
CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease
Soichi Sano et al.
CIRCULATION RESEARCH (2018)
SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells
Yang Liang et al.
LEUKEMIA (2018)
Safety and efficacy of combination therapy of interferon-alpha 2 and ruxolitinib in polycythemia vera and myelofibrosis
Stine Ulrik Mikkelsen et al.
CANCER MEDICINE (2018)
Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study
Kasper M. Pedersen et al.
CANCER MEDICINE (2018)
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
Graeme Greenfield et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms
Gabriela S. Hobbs et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib
Mads Emil Bjorn et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
Morten Andersen et al.
PLOS ONE (2017)
Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications
Lorena Arranz et al.
BLOOD REVIEWS (2017)
Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis
Jinming Song et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2017)
Germline RBBP6 mutations in familial myeloproliferative neoplasms
Ashot S. Harutyunyan et al.
BLOOD (2016)
Hematological manifestations and complications of Gaucher disease
Silvia Linari et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Physiologic Expression of Sf3b1K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation
Esther A. Obeng et al.
CANCER CELL (2016)
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
Takafumi Shimizu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma
Shiny Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
ASXL1 plays an important role in erythropoiesis
Hui Shi et al.
SCIENTIFIC REPORTS (2016)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations
Emmanuelle Verger et al.
BLOOD (2015)
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Naveen Pemmaraju et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Pathogenesis of myeloproliferative neoplasms: More than mutations
Sylvie Hermouet
EXPERIMENTAL HEMATOLOGY (2015)
Pathogenesis of myeloproliferative neoplasms
Radek C. Skoda et al.
EXPERIMENTAL HEMATOLOGY (2015)
Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
Vladan P. Cokic et al.
MEDIATORS OF INFLAMMATION (2015)
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
Sylvie Hermouet et al.
MEDIATORS OF INFLAMMATION (2015)
Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
Holly L. Geyer et al.
MEDIATORS OF INFLAMMATION (2015)
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
Hans Carl Hasselbalch et al.
MEDIATORS OF INFLAMMATION (2015)
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies
Joseph Saliba et al.
NATURE GENETICS (2015)
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
William Tapper et al.
NATURE COMMUNICATIONS (2015)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms
Edwin Chen et al.
BLOOD (2015)
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator
Takuro Kameda et al.
BLOOD (2015)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
Community-acquired infections and their association with myeloid malignancies
Glen J. Titmarsh et al.
CANCER EPIDEMIOLOGY (2014)
The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms Open
A. Oddsson et al.
LEUKEMIA (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms
Hans C. Hasselbalch
EXPERT REVIEW OF HEMATOLOGY (2014)
The role of cytokines in the initiation and progression of myelofibrosis
Hans C. Hasselbalch
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study
A. Pardanani et al.
LEUKEMIA (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
Thomas Stauffer Larsen et al.
LEUKEMIA RESEARCH (2013)
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hans Carl Hasselbalch
LEUKEMIA RESEARCH (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treating inflammation by blocking interleukin-1 in humans
Charles A. Dinarello et al.
SEMINARS IN IMMUNOLOGY (2013)
Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis
Rakhee Vaidya et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hans Carl Hasselbalch
BLOOD (2012)
Dnmt3a is essential for hematopoietic stem cell differentiation
Grant A. Challen et al.
NATURE GENETICS (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?
Sylvie Hermouet et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes
Sigurdur Y. Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F
M. Boissinot et al.
ONCOGENE (2011)
Molecular pathways and targets in cancer-related inflammation
Alberto Mantovani et al.
ANNALS OF MEDICINE (2010)
Autoimmunity and the risk of myeloproliferative neoplasms
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population
Lynnette R. Ferguson et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2010)
Risks of myeloid malignancies in patients with autoimmune conditions
L. A. Anderson et al.
BRITISH JOURNAL OF CANCER (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
J-J Kiladjian et al.
LEUKEMIA (2008)
Inflammation and cancer: An ancient link with novel potentials
S. Perwez Hussain et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders
Christine Bellanne-Chantelot et al.
BLOOD (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease
R Kralovics et al.
BLOOD (2003)
Interferon-α activates multiple STAT signals and downregulates c-Met in primary human hepatocytes
S Radaeva et al.
GASTROENTEROLOGY (2002)
分享论文
